CheckMate-9ER Trial

[Slide 1] 20 ASCO®Genit Participate using the AS Meetings --- [Slide 2] CheckRate YES ORR per BICR in the ITT population ORR per BICR BOR per BICR and depth of response 70 with NIVO+CABO ORR, 55.7% 60 (95% CI, 50.1-61.2) Unknown PD Objective response rate (%) 50 5.6% CR CR 6.5% 13.9% 40 ORR, 27.4% PR with 60% 30 (95% CI, 22.7-32.6) tumor reduction: CR SD PR 20.1%* 20 32.2% PR 10 PR 41.8% PR with 60% 0 tumor reduction: NIVO+CABO SUN 21.7%* (N 323) (N 328) Redies - 47. trange, - ETT pepulation). and both - based - - BOX - - 20 ASCO Genit E - BOX I LINE X - = - PO, I Participate using the Meetings mobile app or at meetings.asco.org

[Slide 1] CheckMate 9ER Summary Long-term efficacy benefit was observed with NIVO+CABO over SUN in these final results from the CheckMate 9ER trial, with a median of 67.6 months of follow-up Safety and tolerability with long-term follow-up were manageable and consistent with previous follow-ups1-3 The results continue to support NIVO+CABO as a standard of care for previously untreated aRCC - As subcutaneous NIVO has been shown to provide clinical equipoise to standard IV dosing, 4 it could be considered as an alternative for patients with aRCC5-7 1. Choueiri TK, et al. N Engl J Med 2021;384:829-841. 2. Motzer RJ, et al. Lancet Oncol 2022;23:888-898. 3. Powles T, et al. ESMO Open 2024;9:102994. 4. Albiges L, et al. Ann Oncol 2025;36:99-107. 5. OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) [package insert]. Princeton, NJ: Bristol Myers Squibb; December 2024. 6. Lonardi S, et al. Poster presentation at the ASCO 2021 Annual Meeting; June 4-8, 2021; Virtual. Poster 2575. 7. Zhao Y, et al. Poster presentation at the SITC 2024 Annual Meeting; November 6-10, 2024; Houston, TX. Poster 524. Copies of this slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO or the author of this slide deck

[Slide 1] Study design: CheckMate 9ER Stratification factors IMDC risk score N = 651 Tumor PD-L1 expression Geographic region Key inclusion criteria¹ Nivolumab 240 mg IV Q2W Previously untreated advanced or + Cabozantinib 40 mg PO QDb metastatic RCC R 1:1 Clear cell component Sunitinib 50 mg PO QD, cycle of 4 weeks on/ Any IMDC risk group 2 weeks offb Median (range) follow-up for OSᶜ in the Primary endpoint: PFS per BICR (RECIST v1.1) ITT population, 67.6 (60.2-80.2) months Key secondary endpoints: OS, ORR per BICR (RECIST v1.1), safety Database lock, June 21, 2024 All analyses presented are descriptive and exploratory "Defined as the percentage of positive tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC 28-8 pharmDx immunohistochemistry assay. Patients were treated until RECIST v1.1-defined progression or unacceptable toxicity. NIVO dosing may not exceed a total of 2 years (from cycle 1); CABO and SUN treatment may continue beyond 2 years in the absence of progression or unacceptable toxicity. Patients may be treated beyond progression. Follow-up was defined as the time from patient's randomization date to last patient last visit date; median follow-up represents the median of individual follow-up periods of all randomized patients. Minimum follow-up was defined as the time from the last patient randomization date to the last patient last visit date. Maximum follow-up was defined as the time from first patient randomization date to last patient last visit date. 1. Choueiri TK, et al. N Engl J Med 2021;384:829-841. --- [Slide 2] OS in the ITT population 100 Median os (95% CI), months 90 NIVO+CABO 46.5 (40.6-53.8) 80 SUN 35.5 (29.2-42.8) Overall survival probability (%) 70 HR (95% CI), 0.79 (0.65-0.96) 58.7% 60 48.9% 50 49.5% 40.9% 40 39.4%; LILL 30 35.4% 20 10 0 0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 Months No. at risk NIVO+CABO 323 298 272 250 222 208 183 164 149 132 122 79 18 0 0 SUN 328 277 243 218 190 169 154 138 120 113 103 59 14 1 0 Median follow-up, 67.6 (range, 60.2-80.2) months (ITT population). Stratified Cox proportional hazards model used for HR.

[Slide 1] ASCO 2024 ASCO Charlene Mantia ANNUAL MEETING Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma Charlene M. Mantia,¹ Opeyemi A. Jegede,¹ Hollis Viray,2 Michael B. Atkins,³ Lisa Rosenblatt,4 Xin Yin,4 David F. McDermott,² Meredith M. Regan¹ Dana-Farber Cancer Institute, Boston, MA; 2Beth Israel Deaconess Medical Center, Boston, MA; ²Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; 4Bristol Myers Squibb, Princeton, NJ Abstract number 4507 --- [Slide 2] ASCO Background Charlene Mantia As multiple treatment options with similar efficacy are approved for 1L treatment of aRCC,¹ it is increasingly important to characterize how patients spend survival time from 1L treatment initiation An integrated, comprehensive partitioned survival analysis describes how patients spend OS time, on/off treatment and with/without toxicity, which is not captured by standard outcome measures² 100 Time-to-event endpoints OS: time from randomization until death or censored at 90- date last alive Death 80- Time to subsequent therapy initiation or death: 70 time from randomization until subsequent systemic anticancer therapy initiation or death, whichever occurred Patients (%) 60- first, or censored at date last known alive and free of Survival after subsequent 50 subsequent therapy therapy initiation 40- TFS with toxicity Time to cessation of both protocol therapy and toxicity time to protocol therapy cessation plus number of days 30- TFS without taxicity* with toxicity after therapy cessation 20 Time on protocol therapy with toxicity Time to protocol therapy cessation: time from 10- randomization until cessation of protocol therapy or Time on protocol therapy without toxicity censored at date last known alive on protocol therapy 0- 0 6 12 18 24 30 36 42 Time to cessation of protocol therapy without toxicity: Months since randomization time to protocol therapy cessation minus number of days on protocol therapy with toxicity Areas under and between Kaplan-Meier curves are restricted mean times. Time after cessation of protocol therapy without toxicity, before initiation of subsequent systemic anticancer therapy, or death. Time after cessation of protocol therapy with toxicity while treatment-free. Includes toxicity persisting since protocol therapy and toxicity newly presenting after protocol therapy cessation. Reused from Regan MM, et al. Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial. Clin Cancer Res 2021;27:6687-6695. Licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. 1. Samuelly A, et al. J Clin Med 2024;13:307. 2. Regan MM, et al. Clin Cancer Res 2021;27:6687-6695. 00000000 --- [Slide 3] ASCO Comprehensive 48-month partitioned survival analysis: TFS with/without grade ≥ 2 TRAEs in the ITT population Charlene Mantia NIVO+CABO SUN 100 100 90 90 80 80 70 70 Patients (%) 60 Patients (%) 60 50 50 49.2% 40 40 40.2% 30 NIVO discontinued 33.3% 30 20 20 15.8%- 10 NIVO+CABO CABO only 10 12,9% 8.2% 0 0 0 6 12 18 24 30 36 42 48 0 6 12 18 24 30 36 42 48 Time since randomization, months Time since randomization, months intent-to-treat Survival state 48-month mean time, months NIVO+CABO SUN Difference (95% CI) (N 323) (N 328) NIVO+CABO vs SUN os 35.1 30.7 Survival after subsequent 5.5 12.0 treatment initiation -6.5 (-8.6 to -4.4) TFS 7.0 4.6 2.4 (0.8-3.9) Without grade E 2 TRAE 3.0 2.3 0.7 (-0.4 to 1.8) With grade 2 2 TRAE 3.9 2.3 1.6 (0.5-2.8) Time on protocol treatment 22.6 14.1 8.5 (6.2-10.8) With grade 2 2 TRAE 8.3 6.7 1.7 (0.1-3.2) Without grade 2 2 TRAE 14.3 7.4 6.8 (4.8-8.8) B --- [Slide 4] ASCO 48-month mean TFS according to baseline subgroups Charlene Mantia Baseline variable 48-month mean TFS, months Difference (NIVO+CABO - SUN) (N for NIVO+CABO/SUN) NIVO+CABO SUN 48-month mean TFS (95% CI), months IMDC favorable (74/72) 6.1 4.3 1.8 (-1.1 to 4.6) Intermediate (188/188) 7.0 4.9 2.0 (0.0-4.1) Poor (61/68) 8.0 4.0 4.0 (0.5-7.5) Region USA/Canada/W. & N. Europe (158/161) 7.0 4.6 2.4 (0.2-4.7) ROW (165/167) 6.9 4.6 2.3 (0.2-4.4) PD-L1 > 1% (83/83) 6.6 3.1 3.5 (0.8-6.1) < 1% / indeterminate (240/245) 7.1 5.1 2.0 (0.1-3.8) KPS s 80 (66/84) 7.7 2.5 5.3 (2.1-8.5) 90 (111/113) 6.4 5.0 1.4 (-1.1 to 3.9) 100(146/129) 7.1 5.4 1.7 (-0.7 to 4.1) Prior nephrectomy, Yes (238/245) 7.5 4.6 2.9 (1.2-4.7) No (85/83) 5.3 4.6 0.8 (-1.9 to 3.5) Bone/liver metastasis, Yes (137/111) 6.0 3.4 2.5 (0.6-4.4) No (186/217) 7.7 5.2 2.5 (0.4-4.6) No. of lesion sites, 1 (63/70) 9.2 6.1 3.1 (-0.7 to 6.9) ≥ 2 (260/258) 6.4 4.3 2.2 (0.6-3.8) Overall 7.0 4.6 2.4 (0.8-3.9) 2-101234567 Favors SUN Favors NIVO+CABO

[Slide 1] CheckMate 9ER Study design: CheckMate 9ER Stratification factors IMDC risk score N = 651 Tumor PD-L1 expression Geographic region Key inclusion criteria Nivolumab 240 mg IV Q2W Previously untreated advanced or + Cabozantinib 40 mg PO QD metastatic RCC R 1:1 Clear cell component Sunitinib 50 mg PO QD, cycle of 4 weeks on/ Any IMDC risk group 2 weeks off Median (range) follow-up for OS in the Primary endpoint: PFS per BICR (RECIST v1.1) ITT population, 67.6 (60.2-80.2) months Key secondary endpoints: OS, ORR per BICR (RECIST v1.1), safety Database lock, June 21, 2024 All analyses presented are descriptive and exploratory Defined as the percentage of positive tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC 28-8 pharmDx immunohistochemistry assay. Patients were treated until RECIST v1.1-defined progression or unacceptable toxicity. NIVO dosing may not exceed a total of 2 years (from cycle 1); CABO and SUN treatment may continue beyond 2 years in the absence of progression or unacceptable toxicity. Patients may be treated beyond progression. Follow-up was defined as the time from patient's randomization date to last patient last visit date: median follow-up represents the median of individual follow-up periods of all randomized patients. 1. Choueiri TK, et al. N Engl J Med 2021;384:829-841.